Bayer Australia Limited has told
the TGA that it will no longer claim
that “Berocca Performance” has
been clinically trialled.
According to the TGA website,
Bayer was responding to a 2010
complaint about the product, with
the company advising that it “has
complied with and will continue
to comply with the regulation 48
decision by the delegate of the
Minister of Health on 15 July 2013”.
Bayer said it has withdrawn
any representations that Berocca
Performance has been clinically
trialled and demonstrated to
improve concentration and reduce
tiredness, and will not use such
representations in any other
advertisement.The above article was sent to subscribers in Pharmacy Daily's issue from 26 Nov 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Nov 13
BREAST Cancer Network Australia (BCNA) has welcomed a PBAC recommendation to subsidise the breast cancer drug Enhertu (trastuzumab deruxtecan) for HER2-low metastatic breast cancer on the PBS.
PHARMACY Connect (PC2024) has revealed that Olympian Peter Bol will be sharing his journey from adversity to athletic greatness at the conference in Sep in Sydney.
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.